News and Announcements
Have you heard about Cashero?
- Published September 21, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Cashero is the all-in-one mobile platform for multi-currency high-yield savings, currency exchange and instant cross-border payments.
We are your money’s superhero. A platform with No hidden fees, No minimum balance, and No stress.
To learn more, watch our video:
Project Summary
Cashero is a project that started back in 2018 and was internally funded from inception to February 2021.
The project has now moved into final stages pre-launch, with the security audit by Trail of Bits now complete.
The application will be available and live for public use in 120+ countries from Fall 2021 where users will be able to download and use the app, benefiting from all its features.
Reason for Equity Sale
Cashero can push to launch without any external funding, however the marketing model has changed to now include the US and more established economies.
App refinement will continue and additional funding will allow Cashero to engage with users in underserved and unbanked areas (Global unbanked population 1.7bn) and expand into more countries within a shorter time frame.
With funding pushing expansion, business growth will come from the increased Userbase and Assets Under Management (AUM). The greater the user base and AUM the greater the interest generated and value of Cashero as a business.
The funding round ends on 30th September 2021 so interested investors must register their interest before this date.
Business Goals
Target Paid user base: 3 – 16m users by December 2024
Target AUM: £5bn – 10bn by December 2024
Exit – Listing on U.K. main market or Nasdaq by December 2024 / Trade sale to Challenger Bank
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
